The Medicines Company (preclinical-stage anti-infective assets) is Buildings and Property in United States that focus on owner business. They cover business area such as owner, operator, preclinical-stage anti-infective asset, proprietary beta-lactamase inhibitor technology, pharmacological property.
-
Owner
-
8 Sylvan Way
Parsippany, NJ 07054
United States
Private
owneroperatorpreclinical-stage anti-infective assetproprietary beta-lactamase inhibitor technologypharmacological property
* We use standard office opening hours in near The Medicines Company (preclinical-stage anti-infective assets)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
The Medicines Company (preclinical-stage Anti-infective Assets) is Buildings and Property business from United States that founded in - ( years old in ), The Medicines Company (preclinical-stage anti-infective assets) business is focusing on Owner.
The Medicines Company (preclinical-stage anti-infective assets) headquarter office and corporate office address is located in 8 Sylvan Way Parsippany, NJ 07054 United States.
The Medicines Company (preclinical-stage anti-infective assets) was founded in United States.
In , The Medicines Company (preclinical-stage anti-infective assets) is currently focus on owner sector.
Above is snippet of Google Trends for "owner" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with The Medicines Company (preclinical-stage anti-infective assets), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
